The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AEGLEA BIOTHERAPEUTICS INC | COM | 00773J103 | 59 | 112,044 | SH | SOLE | 112,044 | 0 | 0 | ||
ABG ACQUISITION CORP I | CL A SHS | G00496102 | 4,978 | 501,300 | SH | SOLE | 501,300 | 0 | 0 | ||
CASTLE BIOSCIENCES INC | COM | 14843C105 | 537 | 20,592 | SH | SOLE | 20,592 | 0 | 0 | ||
SONENDO INC | COM | 835431107 | 586 | 547,945 | SH | SOLE | 547,945 | 0 | 0 | ||
PRENETICS GLOBAL LTD | CLASS A ORD | G72245106 | 95 | 25,000 | SH | SOLE | 25,000 | 0 | 0 | ||
APEXIGEN INC | COM | 03759B102 | 1,085 | 401,757 | SH | SOLE | 401,757 | 0 | 0 |